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Abstract
Background
The efficacy and potential toxicity of rechallenge with combination
ipilimumab and nivolumab has not been described. Retreatment of patients
with immune checkpoint inhibitors in the setting of prior significant toxicity
lacks evidence-based guidance.
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Methods
We present the first three, consecutive patients who received re-treatment
with combination ipilimumab and nivolumab for metastatic melanoma
managed at our institution.
Results
Rechallenge with combination ipilimumab and nivolumab in the setting of
prior grade 3 toxicity with initial combination therapy is feasible, and
responses are seen. We highlight the fact that grade 3 toxicity is likely to
recur, but if so, can be manageable.
AQ1
Conclusions
Retreatment with ipi + nivo may be considered an option in carefully
selected, well-informed patients. More research is required to delineate the
benefits and risks with this approach.
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Abbreviations
ALT Alanine aminotransferase
CT Computed tomography
ECOG Eastern Co-operative Group
FDG 2-Fluoro-2-deoxy-D-glucose
Ipi + nivo Ipilimumab and nivolumab
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irAE Immune-related adverse event
MMF Mycophenolate mofetil
MRI Magnetic resonance imaging
PET-CT Positron emission tomography-computed tomography
RECIST Response evaluation criteria in solid tumours
ULN Upper limit of normal
Introduction
Immune checkpoint blockade with ipilimumab, pembrolizumab and nivolumab
improves overall survival in patients with metastatic melanoma [ 1, 2, 3 ]. The
combination of ipilimumab and nivolumab (ipi + nivo) has the highest response
rate and progression-free survival compared to monotherapy with these agents,
but without mature overall survival data [ 4, 5 ]. However, combination
treatment is associated with severe (grade 3/4) immune-related adverse events
(irAEs) in 55% of treated patients, although the majority is reversible with
appropriate treatment [ 4 ]. Retreatment of patients with immune checkpoint
inhibitors in the setting of prior significant toxicity lacks evidence-based
guidance. We present the case histories of three consecutive patients who were
successfully rechallenged with combination ipi + nivo. All three patients
developed grade 3 toxicity associated with their first combination
immunotherapy treatment. To our knowledge, this is the first report of patients
rechallenged with ipi + nivo.
Case presentations
Case 1
A 62-year-old lady presented in April 2013 with a breast mass found to be
BRAF-mutant metastatic melanoma. A staging scan revealed subcutaneous and
lung metastases. Her past medical history included two primary melanomas in
2007 and 2008, asthma requiring inhaled steroids and brain radiotherapy to a
cavernoma around age 40. She was enrolled into the CheckMate-067 trial
(NCT0184405) and was randomised to ipi + nivo in August 2013. Lactate
dehydrogenase (LDH) was normal.
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Three weeks following cycle 1 she was admitted to hospital with frontal
headaches, nausea and vomiting and an elevated alanine aminotransferase
(ALT) at 107 U/L (upper limit of normal (ULN): <40). As the headaches
responded to analgesia, steroids were withheld. Lumbar puncture revealed a
leukocytosis with elevated protein, but no evidence of infection. A provisional
diagnosis of immune-related aseptic meningitis was made. ALT peaked at 216
on day 4 of the admission and then improved. A hepatitis screen was negative.
Cycle 2 was administered one week following discharge in early September
2013. Less than a week following treatment, her headaches recurred and she
was re-admitted for observation, but discharged after 4 days. Her ALT remained
elevated during this time (106 U/L at admission, 200 U/L at discharge). Again,
steroids were withheld. Close monitoring subsequent to discharge revealed
deteriorating liver function with an ALT peak of 536 one week later (cycle 2,
day 21) prompting admission again and initiation of prednisolone 60 mg daily.
A rapid improvement ensued. The first staging computed tomography (CT) scan
was performed in October 2013 and confirmed a partial response by RECIST
1.1. Prednisolone was weaned over a month. ALT remained within the normal
range for 6 months and restaging revealed further response.
In April 2014 routine biochemistry assessments revealed a flare of immune-
related hepatitis with an ALT of 380 U/L prompting admission for intravenous
methylprednisolone 1 mg/kg. Upon reduction in the ALT 5 days later, treatment
was changed to prednisolone 30 mg and weaned over 4 weeks. Liver function
remained normal for several months and 6 weekly CT scans confirmed the
ongoing partial response.
A re-staging CT scan in November 2014 was suggestive of right hilar nodal
progression, confirmed with positron-emission tomography (PET)-CT. With
hindsight, slight progression was evident on the CT scan in May 2014, shortly
after recommencement of prednisolone. Given it was a single-site relapse in the
context of medium-term disease stability, radiotherapy was administered to this
region.
Progressive disease was again noted in September 2015, this time in
parenchymal lung lesions. A decision was made to rechallenge the patient with
ipi + nivo. ECOG performance status was 0, and her LDH was normal at this
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time. After cycle 2, she developed grade 3 colitis requiring admission and
treatment with IV methylprednisolone 1 mg/kg. A sigmoidoscopy showed no
evidence of macroscopic colitis, but evidence of microscopic inflammation on
biopsy. Concurrent with the diarrhoea, her ALT began to rise again, peaking at
220 U/L before spontaneously falling prior to steroid initiation. Repeat viral
hepatitis serology was negative. A re-staging CT performed in early November
2015 revealed a mixed response to treatment, with new mediastinal
lymphadenopathy but regression of pulmonary nodules.
On day 10 of the admission, methylprednisolone was changed to oral
prednisolone 75 mg. ALT at this time was 102 U/L. Two days later it increased
to 883 U/L and both IV methylprednisolone at 2 mg/kg and mycophenolate
mofetil (MMF) 500 mg bd were commenced. The ALT began to fall
immediately, returning to normal (30 U/L) 3 weeks later. During this time,
corticosteroids and mycophenolate were weaned. A further CT scan performed
2 months after cycle 2 of ipi + nivo showed reduction in the mediastinal nodal
mass and barely discernible pulmonary nodules. She remained on MMF for
6 months and still continues on low-dose prednisolone (5 mg) (8 months total
steroid duration). Her ALT has remained mostly within the normal range. She
has not progressed on routine imaging surveillance. The timeline of the multiple
hepatitis episodes in relation to ipi + nivo treatment and other toxicities is
depicted in Fig. 1 .
Fig. 1
Chronology in Case 1 of recurrent hepatitis in context of combination
ipilimumab/nivolumab treatment, response, other immune-related toxicity and use
of immunomodulatory medication. ALT Alanine aminotransferase, PR partial
response, PD progressive disease, ULN upper limit of normal, RTx radiotherapy,
MMF mycophenolate mofetil
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Case 2
A 68-year-old gentleman presented with BRAF-mutant metastatic melanoma in
July 2015. He had a large pulmonary mass with a pleural effusion, and ECOG
performance status was 2. He had no past medical history of note. LDH was
normal. First-line treatment with ipi + nivo was administered. Two weeks after
his first cycle, he presented with back pain, leg weakness and paraesthesia. MRI
spine and brain were unremarkable. Over the following 24 h, his neurological
status deteriorated with further weakness and IV methylprednisolone 2 mg/kg
was initiated. Consultant neurology input was sought, and a diagnosis of lumbar
plexopathy was made. Concurrent with the neurological toxicity a grade 3
hepatitis was noted, with a peak ALT of 426U/L (ULN < 40U/L). Improvement
occurred in both his neurological status and liver function with
methylprednisolone, and this was eventually converted to oral prednisolone
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100 mg and a slow wean was instituted. Further treatment was withheld. Both
adverse events resolved completely.
A restaging CT scan performed 8 weeks after cycle 1 ipi + nivo showed a partial
response in the lung lesion. Unfortunately, a scan 4 weeks later demonstrated
progressive disease and treatment with dabrafenib and trametinib was
commenced. After 7 months of disease control on therapy, his disease
progressed again in the lung. A decision was made to rechallenge him with
ipi + nivo, under the cover of prednisolone 30 mg daily to mitigate severe
toxicity. ECOG performance status was 1 at this point, and LDH was elevated
(279U/l; ULN 192U/l). He tolerated the first 3 cycles of treatment well and
prednisolone was weaned to 10 mg. LDH normalised after one cycle of therapy.
Ten days after cycle 3, he developed Grade 3 diarrhoea and was admitted for IV
methylprednisolone 2 mg/kg. Due to inadequate control of symptoms,
infliximab was initiated 24 h later. A re-staging CT scan again demonstrated
response in the lungs (see Fig. 2 ). His diarrhoea improved 24 h after
infliximab, and he was changed to prednisolone 70 mg on a weaning schedule.
Three weeks later he required re-admission for recurrent immune-related
diarrhoea and was managed with IV methylprednisolone 2 mg/kg and further
infliximab. He improved rapidly and was discharged on 120 mg prednisolone.
Repeat imaging 6 weeks from the prior CT demonstrated a slight increase in
tumour size, but overall the disease is considered stable. Maintenance
nivolumab has been commenced despite steroid dependent-diarrhoea
(prednisolone maintained at 30 mg).
Fig. 2
Efficacy of rechallenge combination ipilimumab and nivolumab in Case 2—CT
scan at baseline (left) and after 2 cycles (right)
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Case 3
A 39-year-old lady was diagnosed in September 2013 with relapsed BRAF-
mutant melanoma following presentation with back pain, one year from
completion of adjuvant bevacizumab for Stage III melanoma (on the AVAST-M
trial, Eudra-CT number 2006-005505-64). Cross-sectional imaging
demonstrated tumours in the liver, porta hepatis and superior retroperitoneum,
and LDH was elevated (386U/l; ULN 192U/l). Her past medical history was
unremarkable. ECOG performance status was 0. She was enrolled in the
CheckMate-067 trial and was randomised to receive combination ipi + nivo,
followed by nivolumab maintenance. Cycle 1 was administered in late October
2013. The first 18 months of treatment were complicated only by grade 1 rash
with pruritus. In addition, she had a partial response by RECIST 1.1 seen on her
first two re-staging CTs, followed by a sustained partial response.
Three weeks following cycle 12 (in maintenance nivolumab phase), the patient
developed grade 2 diarrhoea and grade 2 nausea. Oral prednisolone (30 mg) was
prescribed as an outpatient and down-titrated over four weeks. Domperidone
proved efficacious for nausea. The diarrhoea reduced to grade 1 after 4 days of
prednisolone and had normalised by 14 days. Stool cultures were negative for
infection, and blood tests were unremarkable. Ten days after completing the
course of oral prednisolone, the diarrhoea recurred (grade 3) and she was
admitted for intravenous methylprednisolone (1 mg/kg) and nivolumab was
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ceased. The methylprednisolone dose was doubled on the second day due to a
lack of improvement. Flexible sigmoidoscopy revealed no macroscopic nor
microscopic abnormality. She was discharged with oral prednisolone (60 mg)
3 days later, and this was weaned successfully over 6 weeks.
The restaging CT at 35 months unfortunately demonstrated enlarging portocaval
lymphadenopathy. Given the excellent initial response observed with ipi + nivo
and complete resolution of diarrhoea, our patient was rechallenged with
ipi + nivo in February 2016. LDH was normal, and ECOG performance status
remained 0. A CT scan after 4 cycles revealed a reduction in size of all
measurable disease, consistent with a partial response. No toxicities were
observed during the rechallenge. At the patient’s request, maintenance
nivolumab was deferred. A follow-up CT 5 months after initiation of treatment
was stable. Another CT 4 weeks later confirmed ongoing disease control.
Discussion
Although retreatment of patients with ipilimumab after an initial period of
disease control may be effective without excessive toxicity [ 6 ], to our
knowledge this is not yet described for the combination of ipi + nivo. We report
the details of three patients successfully rechallenged with ipi + nivo, resulting
in disease response. In two of our patients, this occurred over 2 years from the
initial treatment and in one, 12 months from first cycle of ipi + nivo. In each
situation, grade 3 toxicities were seen with initial therapy, two during the
induction phase resulting in early discontinuation, the other in the maintenance
nivolumab phase.
In Cases 1 and 2, rechallenge was associated with significant immune-related
toxicities: grade 3 diarrhoea and grade 4 hepatitis in one patient and grade 3
diarrhoea in the other (despite ongoing prednisolone). For Case 1, the recurrent
hepatitis manifested as a significant biochemical change only and was never
associated with symptoms, synthetic dysfunction or coagulopathy. Prolonged
immunomodulation with both prednisolone and mycophenolate was required,
however. The diarrhoea necessitated hospital admission, though it improved
with steroid treatment and endoscopically did not meet criteria for colitis. The
diarrhoea in Case 2 required initiation of infliximab due to inadequate
improvement with corticosteroids alone. In Case 3, no recurrence of diarrhoea
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was noted with combination rechallenge, nor any other toxicities of note. This
scenario differed from the other two in that the original toxicity did not occur
during combination therapy, but later in the maintenance phase.
Case 1 in particular reaffirms the potential for durable responses with
combination ipi + nivo despite toxicity. From a large retrospective series, there
is no suggestion that patients treated with ipilimumab who developed toxicity
have their outcomes compromised by immune modulation [ 7 ]. Accordingly, in
the Checkmate-067 trial, of the 120 patients (36%) who discontinued
combination treatment early due to toxicity, 81 (68%) experienced a complete
or partial response [ 4 ]. The median duration of response in this group who
discontinued early was 13 months, comparable with the overall population
(12 months) [ 8 ]. We also acknowledge that there were a number of favourable
prognostic factors present in all our patients upon rechallenge—normal LDH in
Cases 1 and 3, M1b disease in Cases 1 and 2, ECOG performance status of 0 or
1 in all cases.
Occurrence of multiple concurrent toxicities is more common with the
combination of ipi + nivo than with either agent as monotherapy [ 8 ]. In the
reported subgroup analyses from the CheckMate-067 trial, 2 irAEs occurred in
25% (vs 5 and 8% with nivolumab and ipilimumab monotherapies respectively),
3 in 5% (vs 1 and 1%) and >3 in 2% (vs 0 and 0%) of those treated with
ipi + nivo. Interestingly, in Case 1, our patient appeared to have a predisposition
to recurrent hepatitis, but developed a second, different irAE in conjunction
with this after each treatment episode. Notably, she developed hepatitis for the
second time 7 months from her first combination treatment. This is indicative of
prolonged immune activation which may have also accounted for her durable
initial response. Prolonged steroids have been warranted this occasion to control
the hepatitis—over 8 months—in contrast to the median time to resolution of 4–
8 weeks as previously reported in ipi + nivo studies [ 4, 9 ].
Rechallenge immune checkpoint blockade with combination ipi + nivo may be
efficacious, although there is potential for substantial toxicity. These cases
demonstrate that toxicity is likely to recur early in people who originally
developed adverse events during their induction phase. We also demonstrate
that toxicity remains manageable, although is potentially prolonged. The
risk/benefit ratio of rechallenge must be considered on an individual basis and
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informed discussions of potential risk with patients remain important in this
setting. More research is required to determine the optimal schedule for
rechallenge and to quantify the risks involved.
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